Advisory panel OKs Evista to reduce breast cancer risk

Share this article:

An FDA advisory panel voted to back Eli Lilly's request to tell patients its osteoporosis treatment Evista (raloxifene) also helps reduce the risk of breast cancer, despite concerns over the drug's cardiovascular side effects.

The panel of outside experts voted 10-4 in favor of allowing Lilly to re-label Evista as cutting the “risk of invasive breast cancer in women at high risk for breast cancer.”

The panel also voted 8-6 to state Evista cuts breast cancer risk “in postmenopausal women with osteoporosis.”
The votes amount to an advisory panel recommendation to approve Lilly's request to re-label and market Evista as a breast cancer reduction drug.

The FDA often follows the advice of its advisory panels, although it is not required to do so.

The panel based its recommendations on the results of four studies presented by Lilly, including results of a large National Cancer Institute Study examining Evista and an older drug tamoxifen, in relation to preventing breast cancer.

The study of nearly 20,000 postmenopausal women showed that Evista and tamoxifen cut the risk of women developing breast cancer by nearly 50%.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...